GlassScriptPhysician profile
Troy A Beaucoudray
NPI 1316105182
$8,104.89
in general payments reported to CMS, 2019-2025
38 companies · $947 in 2025
The $947 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $790 · 2021: $1,517 · 2022: $1,376 · 2023: $1,263 · 2024: $1,093 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,302.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,187.18 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Collegium Pharmaceutical, INC. | $1,124.96 | 2019-2025 | Xtampza, Belbuca |
| Amgen INC. | $817.99 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $668.61 | 2019-2023 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $401.08 | 2019-2021 | |
| Virtus Pharmaceuticals LLC | $319.79 | 2023-2025 | Levorphanol Tartrate |
| Lundbeck LLC | $317.63 | 2022-2025 | Vyepti |
| Scilex Pharmaceuticals INC. | $306.89 | 2019-2025 | |
| Redhill Biopharma INC. | $246.97 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.94 | 2020-2025 | Relistor |
| Almatica Pharma LLC | $207.62 | 2021-2023 | Gralise |
| Allergan, INC. | $125.11 | 2020 | |
| Upsher-Smith Laboratories LLC | $122.03 | 2021-2022 | |
| Pfizer INC. | $117.45 | 2019-2025 | |
| Ucb, INC. | $109.92 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $84.77 | 2019-2021 | |
| Biotronik Nro, INC. | $80.69 | 2025 | Prospera |
| Axsome Therapeutics, INC. | $71.18 | 2025 | Symbravo |
| Valinor Pharma, LLC | $68.50 | 2023-2025 | Movantik |
| Lilly USA, LLC | $68.36 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $61.69 | 2022-2023 | Quviviq |
| Sk Life Science, INC. | $47.39 | 2021-2022 | |
| Sentynl Therapeutics, INC. | $45.39 | 2019 | |
| Azurity Pharmaceuticals, INC. | $44.71 | 2024 | Horizant |
| Vertex Pharmaceuticals Incorporated | $31.03 | 2024-2025 | |
| Impel Pharmaceuticals INC. | $24.31 | 2022 | |
| Grt US Holding, INC. | $22.68 | 2022 | |
| Biogen, INC. | $21.68 | 2025 | Skyclarys |
| Otsuka America Pharmaceutical, INC. | $20.16 | 2023 | Abilify Maintena, Rexulti |
| Astrazeneca Pharmaceuticals LP | $17.55 | 2019 | |
| Akcea Therapeutics, INC. | $15.71 | 2019 | |
| Impel Pharmaceuticals LLC | $15.03 | 2024 | Trudhesa |
| Daiichi Sankyo INC. | $14.84 | 2019 | |
| Eisai INC. | $13.99 | 2021 | |
| Shionogi INC | $12.65 | 2019 | |
| Zyla Life Sciences, INC. | $12.04 | 2019 | |
| Horizon Therapeutics Plc | $11.52 | 2021 | |
| Forte Bio-Pharma LLC | $1.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Beaucoudray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.